EUVIMEDEUVIMED entdecken
FallberichtLeserbrief

Combined immunotherapy with ipilimumab plus nivolumab in metastatic PD‐1 / PD‐L1 ‐refractory Merkel cell carcinoma—a case report

Anna-Sophia Leven, Jürgen C Becker, Christoph Pöttgen, Dirk Schadendorf, Selma Ugurel, Alpaslan Tasdogan

International Journal of Dermatology · 2024

DOI: 10.1111/ijd.16986 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Anna-Sophia Leven und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Skin Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Merkel CellSkin NeoplasmsHumansNivolumabIpilimumabProgrammed Cell Death 1 ReceptorB7-H1 AntigenImmunotherapyAntineoplastic Combined Chemotherapy Protocols

Substanzen

NivolumabIpilimumabProgrammed Cell Death 1 ReceptorB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Dermatology, Venereology and Allergology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Translational Skin Cancer Research, University Medicine, Essen, Germany.
  • German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Department of Radiotherapy, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, Essen, Germany.
  • German Cancer Consortium, Partner Site Essen, Essen, Germany.
  • National Center for Tumor Diseases (NCT)-West, Campus Essen, & Research Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany.

Zitieren

APA

Leven, A. S., Becker, J. C., Pöttgen, C., Schadendorf, D., Ugurel, S., & Tasdogan, A. (2024). Combined immunotherapy with ipilimumab plus nivolumab in metastatic PD‐1 / PD‐L1 ‐refractory Merkel cell carcinoma—a case report. International Journal of Dermatology. https://doi.org/10.1111/ijd.16986

Vancouver

Leven AS, Becker JC, Pöttgen C, Schadendorf D, Ugurel S, Tasdogan A. Combined immunotherapy with ipilimumab plus nivolumab in metastatic PD‐1 / PD‐L1 ‐refractory Merkel cell carcinoma—a case report. International Journal of Dermatology. 2024. doi:10.1111/ijd.16986

BibTeX
@article{Leven2024,
  author = {Leven, Anna-Sophia and Becker, Jürgen C and Pöttgen, Christoph and Schadendorf, Dirk and Ugurel, Selma and Tasdogan, Alpaslan},
  title = {Combined immunotherapy with ipilimumab plus nivolumab in metastatic PD‐1 / PD‐L1 ‐refractory Merkel cell carcinoma—a case report},
  journal = {International Journal of Dermatology},
  year = {2024},
  doi = {10.1111/ijd.16986}
}
Kostenlos starten →